New Alzheimer's Disease Gene Identified
Researchers Say Gene May Help Reveal People at Risk of Developing Alzheimer's
WebMD News Archive
July 14, 2009 (Vienna, Austria) -- A newly identified gene may help predict
who will develop Alzheimer's disease and the
approximate age at which symptoms of the disorder will begin to appear.
The new gene, dubbed TOMM40, may be the most highly predictive gene
discovered in Alzheimer's disease, according to lead researcher Allen Roses,
MD, director of the Deane Drug Discovery Institute at Duke University Medical
Roses should know; he discovered the variants in the ApoE gene that are
associated with an increased risk for Alzheimer's disease.
The ApoE gene comes in one of three forms: ApoE2, ApoE3, and ApoE4. The
ApoE4 variant is the most dangerous; it accounts genetically for 50% of
late-onset cases of Alzheimer's disease. Adding in TOMM40 may help to pinpoint
up to 90% of inherited cases of the disease, Roses says.
Perhaps more importantly, TOMM40 may help explain why many people with the
most common version of the gene, ApoE3, also get the disease, Roses says.
TOMM40 can also help predict the onset of symptoms within a five- to seven-year
window among people over age 60, he tells WebMD.
The study was presented at the Alzheimer's Association 2009 International
Conference on Alzheimer's Disease.
New Alzheimer's Drugs Needed
If borne out through additional research, testing for the two genes could
help doctors better calculate patients' estimated disease risk and age of
onset, Roses says.
Having genes that can pinpoint who will develop Alzheimer's disease before
symptoms develop will be beneficial once drugs to prevent or slow the
course of the disorder become available, says William Thies, PhD, chief medical
and scientific officer at the Alzheimer's Association.
"But right now, without a treatment to offer, it doesn't do the clinician
much good to know who is at increased risk," he tells WebMD.
ApoE4 testing has been available for some time, and it's apparent that
people do not want testing in the absence of treatment, Thies says. For now,
testing is most useful for drug companies who want to enroll high-risk people
in clinical trials, he says.
Currently, there are 5.3 million Americans living with Alzheimer's disease, which disrupts memory,
learning, and other mental functions. By 2010, there will be nearly half a
million new cases each year, and by 2050, there will be nearly a million new
cases annually, according to the Alzheimer's Association.
For the study, the researchers performed detailed genetic screening on 35
patients, looking at the area of DNA surrounding the ApoE gene.
They found that TOMM40 linked to ApoE3 in either short or long repeated
sequences, while all ApoE4-linked repeated sequences were long.
Among people with the ApoE3 gene variant, those with the long version of
TOMM40 develop Alzheimer's at an average age of 70, Roses reports. Those with
the short version of TOMM40 and ApoE3 develop it at age 77.
ApoE4 always seems to be attached to the more dangerous, long version of
Thies says that a relatively small number of people were studied, and the
findings need to be replicated in larger groups.
The Duke team is planning a larger study combined with a drug trial aimed at
prevention or delay of disease onset.